Le Vinh Pharma SRL
Le Vinh Pharma reported total assets of 24,139 € at the end of the 2025 financial year (annual accounts filed with the NBB on 01 Jun 2026).
The score of Le Vinh Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +176 % Total assets +67 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Le Vinh Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 01 Jun 2026
- Year ended 31 Dec 2024filed on 24 Jul 2025
- Year ended 31 Dec 2023filed on 17 Jun 2024
- Year ended 31 Dec 2022filed on 16 Jun 2023
- Year ended 31 Dec 2021filed on 20 Jun 2022
Le Vinh Pharma's financial analysis
- Solvency87.1%sector median: 40.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Le Vinh Pharma
Le Vinh Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0823.663.424
- VAT number
- BE0823663424
- Peppol
- Registered · 0208:0823663424 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 05 Mar 2010
- Registered office
- 1300 Wavre
- Latest accounts
- 2025 · filed on 01 Jun 2026
- Activity
- Activities of agents involved in non-specialised wholesale (NACE 46190)
Le Vinh Pharma (SRL) has been based in Wavre since 2010, active in: activities of agents involved in non-specialised wholesale. For 2025, it reports a net profit of 9,124 € and equity of 21,026 €; its revenue is not published. Its solvency stands at 87.1%, above the median of its sector (40.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Le Vinh Pharma
Companies in the same business, of comparable size and area, outside its group.
- Nutrirepair Activities of agents involved in non-specialised wholesale Uccle · balance sheet 7,775 €
- Cirba Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 67,062 €
- BSA Pharmaceuticals Activities of agents involved in the wholesale of other particular products Brussels · balance sheet 117,380 €
- Belderm Wholesale of pharmaceutical and medical goods Woluwe-Saint-Lambert · balance sheet 7,299 €
- Eole S.A .(Eolemed et/OU Testeol) Wholesale of pharmaceutical and medical goods Uccle · balance sheet 3,164 €
- Nahan Benelux Activities of agents involved in non-specialised wholesale Uccle · balance sheet 106,326 €
- BVH Consulting Wholesale of pharmaceutical and medical goods Floreffe · balance sheet 44,707 €
- World Technologie Foods Activities of agents involved in non-specialised wholesale Theux · balance sheet 95,781 €
Frequently asked questions about Le Vinh Pharma
What is the revenue of Le Vinh Pharma?
Le Vinh Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Le Vinh Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0823663424 for Le Vinh Pharma, if the company is VAT-registered. Its company number (CBE) is 0823.663.424.
Where is the registered office of Le Vinh Pharma?
According to the CBE register, the registered office of Le Vinh Pharma is in 1300 Wavre.
What is the equity of Le Vinh Pharma?
At the close of the 2025 financial year, the equity of Le Vinh Pharma amounts to 21,026 €, a solvency of 87.1% of total assets.
Who manages Le Vinh Pharma?
The register lists 1 active mandates at Le Vinh Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Le Vinh Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →